University of Illinois College of Medicine

Real-World Study Shows Equivalent Survival Outcomes for Abiraterone and Enzalutamide in Veterans with Metastatic Prostate Cancer

- A first-of-its-kind real-world comparison of abiraterone and enzalutamide in veterans with metastatic hormone-sensitive prostate cancer found identical survival outcomes between the two treatments. - The study demonstrated comparable median overall survival of 36.2 months across both treatment groups, including in Black veterans and patients with cardiovascular disease. - Veterans Affairs healthcare system prefers abiraterone due to lower cost and generic availability, with 53.7% of veterans receiving androgen receptor inhibitor therapy in 2022. - Researchers recommend that treatment decisions should be guided by cost considerations, drug toxicity profiles, and potential drug-drug interactions rather than efficacy differences.